Monitor Q4 2026 for enrollment completion in ADVANCED-2 and interim THRIVE-3 data, which are the next major catalysts. The ADVANCED-3 redesign is a strategic shift that may delay a registrational path in BCG-Naive patients, increasing uncertainty around the NMIBC program's timeline.
Price Chart
Executive Summary
Protara Therapeutics reported Q2 2026 results with a net loss of $21.7M ($0.36/share), widening from a $15.0M loss in Q2 2025, driven by increased R&D spending on clinical trials. The company highlighted key pipeline milestones: expects to complete enrollment in the BCG-Unresponsive cohort of the ADVANCED-2 trial in Q4 2026, is redesigning the ADVANCED-3 trial as an exploratory study, and remains on track to report interim THRIVE-3 results in Q4 2026. Cash of $161.9M is expected to fund operations into 2028, but the widening losses and trial redesign signal a longer path to commercialization without near-term revenue catalysts.
Key Financial Metrics
Key Facts
- Net loss for Q2 2026 was $21.7 million, or $0.36 per share, compared to a net loss of $15.0 million, or $0.35 per share, in Q2 2025.
- Cash, cash equivalents and investments totaled $161.9 million as of June 30, 2026, expected to support operations into 2028.
- The ADVANCED-3 trial is being redesigned as a multi-cohort, open-label, exploratory trial to study TARA-002 in a broader NMIBC patient population.
- Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in Q4 2026.
- Interim results from the THRIVE-3 registrational trial of IV Choline Chloride are expected in Q4 2026.
- TARA-002 demonstrated clinical success in 83% (10/12) of participants that completed treatment in the STARBORN-1 trial for LMs.
Financial Impact
Net loss widened by $6.7M YoY to $21.7M in Q2 2026; R&D expenses increased by $6.2M to $17.0M.
Risk Factors
- Widening net losses with no near-term revenue prospects increase cash burn rate.
- Redesign of ADVANCED-3 trial introduces uncertainty in the NMIBC development timeline and regulatory path.
- Clinical trial enrollment and data readout risks across all pipeline programs (NMIBC, LMs, IV Choline Chloride).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-087506 |
| Document: ea0299236-8k_protara.htm | 0001213900-26-087506 |
| Document: 0001213900-26-087506-index-headers.html | 0001213900-26-087506 |
| Document: 0001213900-26-087506-index.html | 0001213900-26-087506 |
| Document: 0001213900-26-087506.txt | 0001213900-26-087506 |
| 8-K Data (Synthetic) | 0001213900-26-087506 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access